[Effect of carvedilol on lipid peroxidation in patients with stable angina].
Effect of carvedilol on lipid peroxidation was investigated in patients with stable angina. The study comprised 30 patients (20 men and 10 women), aged 38-55 years (mean 48.3 years) with stable angina. The patients were administered carvedilol in increasing every four weeks doses: 12.5 mg/day, 25 mg/day, 50 mg/day. The control group consisted of 12 healthy subjects aged 39-49 years (mean 45.7 years). Blood samples were collected before and 4,8 and 12 weeks after therapy in patients and once in control group. Our study has been approved by the local Ethics Committee. MDA concentration in plasma and erythrocytes, which is a recognised indicator of tissue injury caused by reactive oxygen species, was measured according to Placer et al. MDA concentration was significantly higher (p < 0.05) in patients with stable angina than in control group. After 4, 8 and 12 weeks of carvedilol therapy, decrease in MDA concentration was observed in comparison to the initial values. MDA concentration did not differ in patients from that observed in healthy subjects after 8 and 12 weeks of therapy The results of our study have shown that carvedilol inhibits lipid peroxidation in patients with stable angina.
Kowalski
Jan
J
Katedra Rehabilitacji z Klinika Chorób Wewnetrznych i Rehabilitacji Kardiologicznej UM w Łodzi.
Błaszczyk
Jan
J
Kowalski
Marcin
M
Cegliński
Tomasz
T
Wróbel
Włodzimierz
W
Irzmański
Robert
R
Krzemińska
Anna
A
Pawlicki
Lucjan
L
D000328:Adult; D000787:Angina Pectoris / Q000188:drug therapy* / Q000378:metabolism*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002227:Carbazoles / Q000008:administration & dosage*; D000077261:Carvedilol; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004912:Erythrocytes / Q000187:drug effects; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000008:administration & dosage*; D017382:Reactive Oxygen Species / Q000737:chemistry / Q000378:metabolism; D012016:Reference Values; D017392:Thiobarbituric Acid Reactive Substances / Q000494:pharmacology; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D002227:Carbazoles; D011412:Propanolamines; D017382:Reactive Oxygen Species; D017392:Thiobarbituric Acid Reactive Substances; D000077261:Carvedilol